Access Pharmaceuticals Announces Clinical Results Of MuGard(TM) At A Major Supportive Care Conference

Main Category: Cancer / Oncology
Also Included In: Radiology / Nuclear Medicine;  Clinical Trials / Drug Trials;  Conferences
Article Date: 23 Jun 2006 - 0:00 PDT

email to a friend   printer friendly   opinions  

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) today announced the clinical results of MuGard(TM) at the 18th International Symposium of the Multinational Association of Supportive Care in Cancer in Toronto, June 22-24. MuGard(TM) is Access' proprietary oral rinse product for the prevention and treatment of oral mucositis, the debilitating side-effect which afflicts more than 20% of cancer patients undergoing radiation and chemotherapy. Access plans to submit a 510(k) application for U.S. marketing approval of MuGard(TM) in the third quarter of this year.

"In our clinical study of head and neck cancer patients receiving radiation therapy, 47% of patients using MuGard(TM) had no mucositis," stated Rosemary Mazanet M.D., Ph.D., CEO of Access. "Historically, patients on the same treatment without MuGard(TM) had a high rate of mucositis, with only 7% of patients experiencing no mucositis. In addition, the number of patients with mild to moderate mucositis was statistically reduced as well by the use of MuGard(TM). There is currently no well-accepted treatment for mucositis, and we believe that these results demonstrate that MuGard(TM) should be a valuable supportive care option for cancer patients." The estimated size of the market for this indication in the U.S. exceeds $1 billion. The Company is actively seeking marketing partners for this product.

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the treatment of patients with mucositis. The Company also has other advanced drug delivery technologies including vitamin-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including statements relating to the value of our products in the market, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2005 and other reports filed by us with the Securities and Exchange Commission.

Access Pharmaceuticals, Inc.
http://www.accesspharma.com

• Additional
• References
• Citations